Treatment Options in BRAF|mutant Metastatic Colorectal Cancer

The Evolving Treatment Landscape in BRAF-V600E–Mutated ...

Novel approaches for managing BRAF-V600E metastatic colorectal cancer include combinations of BRAF inhibitors and anti-EGFR antibodies with immune checkpoint ...

Real-world first-line treatment of patients with BRAFV600E-mutant ...

European guidelines recommend combination (doublet or triplet) chemotherapy plus bevacizumab in first line. However, an unmet need remains for more effective ...

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of ...

Current standard treatment for these tumors involves a combination of chemotherapy (CT) and VEGF inhibitors. Recently, targeted therapy against ...

Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI

For people with colorectal cancer with BRAF mutations, a treatment regimen that consists of three targeted cancer drugs—encorafenib ...

Review Management of BRAF-mutant metastatic colorectal cancer

There are a number of therapeutic options available for patients with BRAF-mutated mCRC (Figure 1B). Systemic chemotherapy has been the foundation of therapy ...

Current Therapeutic Strategies in BRAF-Mutant Metastatic ... - Frontiers

Around 52% of MSI tumors also have BRAF mutations, and 55% of BRAF-mt tumors show MSI (16). Immunotherapy, in particular, immune checkpoint ...

Treatment of patients with BRAF V600E -mutated metastatic ...

Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E-mutated metastatic colorectal cancer ( ...

A Treatment Evolution Is Underway in BRAF V600E–Mutated mCRC

“CRC with a BRAF mutation is a more aggressive form of cancer that doesn't respond to standard chemotherapy. It is more common in women [older ...

Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer - EMJ

Taieb explained that the combination of encorafenib with cetuximab is a new therapeutic option for gastrointestinal oncologists; therefore, ...

BRAF-Mutated Advanced Colorectal Cancer - ASCO Publications

Treatment regimens currently under exploration in BRAFV600E-mutant metastatic colorectal cancer include combinatorial options of various ...

BRAF Mutation Colon Cancer | Know Your Biomarker

The BRAF inhibitors used in advanced colorectal cancer treatment are encorafenib (Braftovi), and vemurafenib (Zelboraf). The MEK inhibitors used in metastatic ...

Treatment Options in BRAF-mutant Metastatic Colorectal Cancer

Treatment options for metastatic colorectal cancer (CRC) have been limited to a cytotoxic chemotherapy with or without an anti-epithelial growth-factor ...

European expert panel consensus on the clinical management of ...

Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations. The BRAFV600E mutation occurs in ...

Treatment Options for BRAF V600E–Mutant Metastatic Colorectal ...

It doesn't work well as a single agent in colorectal cancer vs other cancers. We have to combine it with anti-EGFR therapy, and encorafenib is ...

Treatment of metastatic colorectal cancer with BRAF V600E mutation

BRAF V600E mutant-metastatic colorectal cancer (mCRC) is characterized by its short survival time. Treatment approaches vary depending on whether or not the ...

Exploring the best treatment options for BRAF-mutant metastatic ...

The BRAFV600E mutation is a well-accepted poor prognostic factor in patients with metastatic colorectal cancer (mCRC), as it confers ...

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated ...

Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 ...

Real‐world treatment and outcomes of patients with metastatic ...

BRAF mutation occurs in 5%–10% of metastatic colorectal cancers (mCRCs). Patients with BRAF mutant mCRC exhibit a specific metastatic pattern ...

Immune checkpoint blockade therapy for BRAF mutant metastatic ...

Common inhibitors that block this signaling pathway in the treatment of colorectal cancer include EGFR inhibitors (Cetuximab, Panitumumab), BRAF ...

Glimmers of Hope—New Strategies for Overcoming Treatment ...

BRAF V600E-mutated metastatic colorectal cancer is notoriously difficult to treat due to an aggressive tumor biology and resistance to chemotherapy.